Table 2 Main outcome table. Baseline Montgomery Åsberg Depression Rating Scale (MADRS) scores and change in the depressive symptoms over 52 weeks for patients in the intention-to-treat and per-protocol analysis. Values are means unless stated otherwise. Estimated mean differences and 95% Confidence Intervals (CIs) are presented.
Intention-to-treat MADRS (n = 181) | |||||
|---|---|---|---|---|---|
Usual care + paroxetine (n = 85) | Usual care (n = 96) | Mean difference* | SD | 95% CI | |
Baseline score | 23.7 | 24.1 | |||
6 weeks – baseline† | -7.6 | -6.0 | -1.6 | 20.2 | -4.7; 1.4‡ |
13 weeks – baseline † | -10.2 | -8.7 | -1.5 | 22.5 | -5.1; 1.9 |
26 weeks – baseline † | -13.0 | -10.0 | -3.0 | 21.3 | -6.4; 0.3 |
52 weeks – baseline † | -14.7 | -12.6 | -2.1 | 24.1 | -6.1; 1.9 |
Per-protocol MADRS (n = 133) | |||||
Usual care + paroxetine (n = 55) | Usual care (n = 78) | Mean difference* | SD | 95% CI | |
Baseline score | 25.1 | 24.1 | |||
6 weeks-baseline† | -7.8 | -6.7 | -1.1 | 20.0 | -4.5; 2.4‡ |
13 weeks-baseline† | -12.1 | -9.0 | -3.1 | 20.7 | -6.8; 0.5 |
26 weeks-baseline† | -13.9 | -9.3 | -4.6 | 20.6 | -8.4; -0.9§ |
52 weeks-baseline† | -17.6 | -12.6 | -5.0 | 21.2 | -9.1; -1.0§ |